Trials / Completed
CompletedNCT01428531
Special Drug Use Investigation for Arixtra® (Fondaparinux) Venous Thromboembolism Treatment
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 200 (actual)
- Sponsor
- GlaxoSmithKline · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this post-marketing surveillance study is to collect and assess information on safety and efficacy of fondaparinux injection in patients with venous thromboembolism (VTE). ("Arixtra" is a trademark of the GlaxoSmithKline group of companies.)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Fondaparinux Sodium |
Timeline
- Start date
- 2012-01-01
- Primary completion
- 2015-06-01
- Completion
- 2015-06-01
- First posted
- 2011-09-05
- Last updated
- 2015-07-15
Source: ClinicalTrials.gov record NCT01428531. Inclusion in this directory is not an endorsement.